Shares of Homology Medicines Inc (NASDAQ:FIXX) hit a new 52-week low during trading on Friday . The stock traded as low as $15.60 and last traded at $15.71, with a volume of 115 shares trading hands. The stock had previously closed at $16.30.

FIXX has been the subject of several research reports. Bank of America initiated coverage on Homology Medicines in a research note on Monday, April 23rd. They issued a “buy” rating and a $27.00 target price for the company. BTIG Research initiated coverage on Homology Medicines in a research note on Tuesday, April 24th. They issued a “buy” rating and a $35.00 target price for the company. Evercore ISI initiated coverage on Homology Medicines in a research note on Monday, April 23rd. They issued an “outperform” rating and a $30.00 target price for the company. Finally, Cowen initiated coverage on Homology Medicines in a research note on Monday, April 23rd. They issued an “outperform” rating for the company.

Homology Medicines (NASDAQ:FIXX) last issued its earnings results on Monday, May 14th. The company reported ($4.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.78) by ($0.43). The firm had revenue of $0.82 million during the quarter. equities research analysts expect that Homology Medicines Inc will post -1.74 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Nexthera Capital LP acquired a new stake in shares of Homology Medicines in the 1st quarter valued at about $243,000. Blackstone Group L.P. acquired a new position in Homology Medicines during the 1st quarter valued at about $252,000. Dean Capital Investments Management LLC acquired a new position in Homology Medicines during the 1st quarter valued at about $401,000. Citadel Advisors LLC acquired a new position in Homology Medicines during the 1st quarter valued at about $471,000. Finally, Bank of New York Mellon Corp acquired a new position in Homology Medicines during the 2nd quarter valued at about $558,000. Institutional investors own 48.42% of the company’s stock.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Read More: What are CEFs?

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.